MedTrace Logo

Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, ARVI

NCT05862883 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 301

Last updated 2023-05-17

No results posted yet for this study

Summary

Clinical research includes Determination of efficacy and acceptability of the local medicine "Rutan tablets 0,025" in children and teenagers 6-18 years old with COVID-19 and/or acute respiratory viral infections. And also the purpose of the study was to study clinical and laboratory changes when using Rutan in patients with Covid 19 clinical methods such as collection of anamnesis, dynamic examination of patients, catamnestic observation - a telephone survey, as well as biochemical, immunological, virologic PCR and ELISA tests.

Conditions

  • COVID-19 Respiratory Infection

Interventions

DRUG

Rutan 25 mg

Active ingredient: (3,6-bis-O-galloyl-1,2,4-tri-O-galloyl-β-D-glucose). Active substance: "Rutan 25 mg. Excipients: potato starch, calcium stearate, lactulose.

OTHER

Control group

Taking basic therapy without Rutan

Sponsors & Collaborators

  • Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan

    lead OTHER_GOV

Principal Investigators

  • Erkin Musabaev, professor · +998901869164

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-07-01
Completion
2022-07-01

Countries

  • Uzbekistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05862883 on ClinicalTrials.gov